Discontinued — last reported Q4 '25
Products & Services · Deferred Revenue
C5 License Obligation — Deferred Revenue
Alnylam Pharmaceuticals C5 License Obligation — Deferred Revenue decreased by 100.0% to $0 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $12.02M to $0. Over 3 years (FY 2021 to FY 2024), C5 License Obligation — Deferred Revenue shows a downward trend with a -12.3% CAGR.
Analysis
Metric ID:
alny_segment_c5_license_obligation_deferred_revenueHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.5M | $28.3M | $26.9M | $26M | $30.8M | $30.3M | $7M | $6M | $3.8M | $3.8M | $27.5M | $26.1M | $27.4M | $22.1M | $12.02M | $0 |
| QoQ Change | — | -4.1% | -4.9% | -3.3% | +18.5% | -1.6% | -76.9% | -14.3% | -36.7% | +0.0% | +623.7% | -5.1% | +5.0% | -19.3% | -45.6% | -100.0% |
| YoY Change | — | — | — | — | +4.4% | +7.1% | -74.0% | -76.9% | -87.7% | -87.5% | +292.9% | +335.0% | +621.1% | +481.6% | -56.3% | -100.0% |
Range$0 – $30.8M
CAGR-100.0%
Avg YoY Growth+105.0%
Median YoY Growth-25.9%
Current Streak3 quarters decline
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's c5 license obligation — deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported c5 license obligation — deferred revenue of $0 in Q4 2025.
- How has Alnylam Pharmaceuticals's c5 license obligation — deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's c5 license obligation — deferred revenue decreased by 100.0% year-over-year, from $12.02M to $0.
- What is the long-term trend for Alnylam Pharmaceuticals's c5 license obligation — deferred revenue?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's c5 license obligation — deferred revenue has grown at a -12.3% compound annual growth rate (CAGR), from $129.9M to $87.62M.